Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prulifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prulifloxacin SCHEMBL13896543 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1650794 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1699755 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL29540773 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL7060281 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL13822719 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL28660626 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL9673724 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1231520 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL9674383 | 0.96 | LMNA (0.92) | LMNAPRKD3PIM1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3822 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| EP-4658376-A1 | SKIN CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250346910-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | COMMENSE BIO INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | claimed |
| CN-120131953-A | Targeted nano-drug with sonodynamic activity, and preparation method and application thereof | 中山大学·深圳 | 2025-06-13 | — | — | CN | claimed |
| EP-4554627-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-21 | — | — | EP | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| US-20250144088-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-08 | — | — | US | claimed |
| CN-119875972-A | Methods and compositions for preventing microbial infection | 比奥普来克斯有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1704419-A | Process for synthesis of prulifloxacin and its pharmaceutical composition | HARBIN JIANDI MEDICINE TECHNOL (CN) | 2005-12-07 | — | — | CN | claimed |
| CN-1668598-A | Use of chemotherapeutic agents | SCHULZ & SCHLIMBACH GBR (DE) | 2005-09-14 | — | — | CN | claimed |
| CN-1557314-A | Prulifloxacin water-soluble salt and its injection formulation | 魏雪纹 | 2004-12-29 | — | — | CN | claimed |
| EP-1408034-A1 | Use of Quinoline derivatives as antibacterial agents | Schulz & Schlimbach GbR (DE) | 2004-04-14 | — | — | EP | claimed |
| CN-1478781-A | Preparation method of prolisaxin | 高 杨 | 2004-03-03 | — | — | CN | claimed |
| EP-1244434-A2 | USE OF CHEMOTHERAPEUTIC AGENTS | Schulz, Hans-Herrmann (DE) | 2002-10-02 | — | — | EP | claimed |
| WO-2001045679-A2 | USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT | SCHULZ HANS HERRMANN (DE) | 2001-06-28 | — | — | WO | claimed |
| WO-2000001365-A1 | PROLONGED RELEASE OPHTHALMIC COMPOSITIONS CONTAINING A FLUOROQUINOLONE | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2000-01-13 | — | — | WO | claimed |